SeqLL Inc. Common stock

SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It designs, develops, and manufactures genetic analysis technologies; and offers true single molecule sequencing (tSMS) platform that assists researchers to develop research, diagnostics, and therapeutics applications. The company also provides RNA sequencing services and instruments, which include Direct RNA Sequencing, a genetic testing and mapping service that captures polyadenylated RNA directly without conversion to cDNA; tSMS formalin fixed paraffin embedded (FFPE) service to analyze damaged or fragmented nucleic acids from formalin fixed paraffin embedded samples and other sources; micro RNA sequencing; and custom sequencing, and mapping and testing services, as well as gene expression studies, FFPE RNA Sequencing, biomarker discovery, fusion detection, rare mutation detection, transcriptome profiling, and cap analysis gene expression services. In addition, it offers DNA sequencing services and instruments, such as shotgun DNA sequencing, direct capture sequencing, cell free DNA sequencing, FFPE DNA sequencing, ancient DNA sequencing, and targeted sequencing, as well as microbiome studies, biomarker discovery, and tumor profiling services. Further, the company provides bioinformatics services comprising data processing, biomarkers research, pathway analysis, and gene expression analysis services, as well as undertakes various custom projects. It has a collaboration agreement with Bernstein Laboratory, Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc., and Tetracore, Inc. The company serves academic and government institutions, hospitals and medical centers, pharmaceutical and biotechnology companies, and non-profit research organizations. SeqLL Inc. was founded in 2013 and is based in Woburn, Massachusetts.